Utrecht, December 12, 2014
Mediq today announces that Jesper Boysen, Executive Vice President Nordics and Baltics, will be leaving the company and that Joergen Kelkjaer has been appointed as his successor.
Jesper Boysen joined Mediq in 2006 and has been EVP Nordics & Baltics since 2009. Jesper Boysen was responsible for six acquisitions and therefore played a significant role in building Mediq’s position in the healthcare market in the Nordics and Baltics.
Joergen Kelkjaer is appointed as of 1 January as EVP Nordic & Baltics, joining the company with years of experience executing successful corporate strategies that drive growth. Joergen Kelkjaer has been Managing Director at Tjellesen Max Jenne (part of Celesio) since 2009. Prior to this Kelkjaer has held various management positions for among others Novo Nordisk, NNE Pharmaplan and Nomeco. Kelkjaer has the Danish nationality.
Arthur de Bok, CEO Mediq: “I’d like to thank Jesper for the many years of work that he has contributed to the company. Jesper built the successful foundation for our growth in the Nordics & Baltics. We wish him all the best. At the same time I’m happy Joergen joins the Executive Committee. I’m confident that with his extensive experience, we’re able to further strengthen our international position.”
Mediq supplies medical devices, pharmaceuticals and associated care in 14 countries. The focus of Mediq is to strengthen its international position by driving growth autonomously as well as through acquisitions. Mediq has further intensified the search for acquisitions and therefore appointed Leah Bayer as Director Business Development and Mergers & Acquisitions. Bayer has the American nationality and worked for various companies, including Siemens AG, IBM Consulting Services, Bain & Company, and most recently Davita, a healthcare service provider.